08:02 AM EDT, 08/26/2024 (MT Newswires) -- Ocugen ( OCGN ) said Monday that Health Canada issued a "no objection letter" to a phase 3 clinical trial of OCU400 in retinitis pigmentosa to be conducted in Canada.

The study in Canada, which will run in parallel with the trial in the US, will enroll up to 50 participants 8 years old and older at up to five sites, the company said.

The biotechnology company said its modifier gene therapy candidate previously received orphan drug and regenerative medicine advanced therapy designations from the US Food and Drug Administration.